SAN FRANCISCO, March 23, 2015 /PRNewswire/ -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, today announced its latest version of goBalto Activate. This first major release of 2015 offers new features that further accelerate clinical study startup.
Sponsors and CROs continue to search for ways to reduce the time it takes to get investigative sites up and running. goBalto is at the forefront of fully automating study startup, enabling business process agility and continual process improvements that existing systems don't address.
Recognizing that study startup is more than just documents, goBalto tailored this new Activate release to include submissions and other key activities and milestones not effectively managed with existing clinical systems. To better optimize the entire startup life cycle, Activate provides a more complete and accurate picture of status and bottlenecks.
With over 1,200 CRO and pharmaceutical users in more than 50 countries using Activate to manage, track, and complete study startup tasks, goBalto has the largest set of proven country workflows. These workflows meet the expectations of specific country regulatory submission requirements out of the box, so that companies can start their studies in days.
Activate customers report improved business performance and shorter cycle times. New capabilities just released aim to reduce study startup timelines even more, with a focus on enhanced document management, business process improvement, and alerting. Activate's new features include:
There continues to be a steady increase in enterprise Activate usage, with newly added top 20 pharma and biotech companies starting their first studies in Activate. The addition of goBalto's latest customers represents a 60 percent increase from the same time in 2014.
"Our goal is to continue to support customers who are taking the leadership role to improve study startup," said goBalto CEO Sujay Jadhav. "We're constantly looking for the most innovative ways to provide customers with even more time savings, increased visibility, and enhanced collaboration. With Activate's seamless integration capabilities, we're helping our customers span the entire study startup life cycle, out of the box, from document approval to eTMF ready."
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.